No Prescription |
 |
 | ||
|
Avodart Avodart |
|
| ||
No Prescription » Prescription Drugs 2 » Avodart Avodart Product Origin: EU (Turkey) This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English. Medical Information: Dutasteride prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. DHT is involved in the development of benign prostatic hyperplasia (BPH). Dutasteride is used to treat benign prostatic hyperplasia (BPH) in men with an enlarged prostate. This medicine helps improve urinary flow and may also reduce your need for prostate surgery later on. Treating symptoms of benign prostatic hyperplasia (BPH) or enlargement of the prostate gland. It also helps to reduce the risk of urinary blockage and the need for prostate surgery. Avodart is a 5 alpha-reductase enzyme inhibitor. It works by lowering levels of a hormone called dihydrotestosterone (DHT) which is a major cause of prostate growth. Lowering DHT leads to shrinkage of the enlarged prostate gland. AVODART is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: 1. Improve symptoms. 2. Reduce the risk of acute urinary retention3. Reduce the risk of the need for BPH-related surgery. Buy Avodart Avodart and other Prescription Drugs 2 products online at Medstore. 3639
About Avodart Avodart: Product Type: Prescription Drugs 2 Avodart ( Avodart Duagen Generic Dutasteride ) Avodart (Avodart Duagen Generic Dutasteride) Avodart Duagen Generic Dutasteride 0.5mg 30 Capsules Avodart Duagen Generic Dutasteride Avodart
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
